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Background: Use of antiepileptic drugs during pregnancy can be associated with 
an increased risk of teratogenicity as well as congenital abnormalities. However, 
there are numerous discrepancies to determine whether lamotrigine, as an anti-
epileptic drug, can significantly induce malformation in newborn infants or not. 
Thus, the purpose of the study was to evaluate the teratogenic effects of lamotri-
gine on mouse fetuses.
Materials and methods: In the present study, 21 pregnant mice were assigned to 
four groups. Groups 1 and 2 (controls) received mock treatment and ethanol 20%, 
respectively. Groups 3 and 4 (treatment) were intraperitoneally administered with 
25 and 75 mg/kg lamotrigine for three days, respectively. The treatment protocol 
was performed within the gestational days of 9-18 in all groups. On gestational 
day 18, 117 fetuses were taken out of the fallopian tube of studied mice and then 
examined for any anomalies (vertebral, limbs and cranial), followed by a measure-
ment of their height and weight.
Results: The results revealed that, in the treated groups, the weight and the 
height had significantly decreased (p<0.01) and also various anomalies were evi-
dent. Moreover, as the dose of lamotrigine increased, the decrease in the weight 
and the height and rising trend in anomalies were intensified.
Conclusion: According to the findings, lamotrigine (LTG) could be considered as 
a risk factor for the development of the anomalies examined.
BACKGROUND
Birth defects, congenital deformities, congenital 
anomalies, as well as congenital abnormalities are 
terms similarly referred to deficiencies in structure, 
function, and metabolism leading to physical and 
mental disabilities or death.1 Genetic and environ-
mental factors as well as their potential interactions 
involved in pathogenesis include single gene disor-
ders, chromosomal abnormalities, maternal medical 
conditions, and exposure to environmental toxins, 
substance abuse, infections, drugs, chemicals, radia-
tions, and hyperthermia. The mechanical constraints 
on fetal2 and antiepileptic drugs (AEDs) have been 
reported to affect fetal development throughout preg-
nancy and also increase the risk of major congenital 
abnormalities in the neonates3,4.
According to previous reports, traditional anti-
epileptic drugs such as phenobarbital, phenytoin, 
carbamezapine, and valproate can increase the risk 
of congenital malformations in pregnant women.3,5 
Generally, AEDs are classified into two groups ac-
cording to their risks for pregnancy. The first group 
consists of a number of conventional drugs that 
have been extensively investigated for teratogenic 
effects. The second group, as the newer AEDs, has 
not been confirmed in terms of their teratological 
effects.6,9 In general, LTG can have an acceptable 
safety profile and it can be used as an effective 
medication in the treatment of epilepsy and various 
cognitive disorders.10,11 For example, C9H7Cl2N5 
is a phenyltriazine derivative that is rapidly and 
completely absorbed after oral administration.12,13 
This drug can also act by inhibiting the release of 
glutamate in voltage-dependent sodium channels.
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There are few studies regarding the emergence 
of LTG-induced teratogenic anomalies in pregnancy 
and epilepsy.3,14 Moreover, there are several method-
ological challenges concerning such investigations. 
For example, a small sample size inadequately 
demonstrates possible teratogenic effects of AEDs, 
namely lamotrigine. Furthermore, comprehensive 
interpretations of teratological data have not been 
evaluated in previous studies. Nevertheless, some 
research on animals have shown that oral administra-
tion of LTG in mice and rats induces no teratogenic 
effects, but it can increase preterm birth and fetal 
death.14 In another study by Bastaki et al.15, LTG 
at 25-300 mg/kg in pregnant mice was reported to 
initiate muscle contraction, weight loss, preterm 
birth, as well as craniofacial deformities such as 
cleft palate and exencephaly. However, no vertebral 
and limb anomalies were reported. In the brain of 
rat fetuses receiving lamotrigine, a reduced body 
weight at birth could increase the volume and the 
diameter of the cerebral structure whilst augmented 
density of subcortical layer and ventricle dilatation 
was reported.16 No study has been inclusively con-
ducted to examine the teratogenic effects of LTG in 
humans and most investigations have shed light on 
LTG in combination with other drugs. Therefore, 
the observed fetal complications could not be attrib-
uted merely to LTG. So far, a few research studies 
have been conducted to explore the physiological 
mechanisms of LTG and its potential therapeutic 
applications in mice models of epilepsy17,19 but 
there are limited studies on LTG teratogenicity. 
Additionally, most studies have considered oral 
intake of the drug. Therefore, the purpose of this 
study was to investigate the in vivo teratogenic 
effects of intraperitoneal administration of LTG 
on mice fetuses. Such studies could help further 
understand the negative effects of teratogenes in 
terms of preventing the potential side effects on 
pregnant women and fetuses.
MATERIALS AND METHODS
This experimental study was conducted on 21 
pregnant mice (Pasteur Institute, Tehran, Iran). The 
use of animals in this experiment was approved by 
the Research Committee affiliated to Department of 
Anatomy, School of Health, Shahrekord University 
of Medical Sciences, under the guidelines of the 
National Advisory Committee for Laboratory Animal 
Research20 and National Institute of Health for the 
use of laboratory animals.21 After the animals were 
transferred to the School of Medicine at Shahrekord 
University of Medical Sciences, they were allowed 
to adapt themselves to the new environment at 
21±1°C and 12 h light/dark cycle. Then, three or 
four female mice were kept with one male mouse 
in a cage for breeding. The next morning, the mice 
were examined for vaginal plug and the ones with a 
vaginal plug were isolated. To closely determine the 
onset of pregnancy, the researchers separated male 
and female mice again and the day the vaginal plug 
was noted was considered as day 0 of pregnancy.
It should be noted that pure LTG powder (Hetero 
Drugs Limited, India) is slightly soluble in water, 
so LTG was dissolved in ethanol.22 Ethanol 20% 
(Merck, Germany) modified with 1 ml distilled 
water was used for LTG administration. Since 
ethanol by itself is a potential confounding factor, 
a control group (control 2) was considered which 
was administered with ethanol alone.
It has been established that LTG at a dose of 25 
mg/kg can act as a teratogen and it can also lead to 
the death of mice at doses higher than 75 mg/g.18 
Therefore, a dose range of 25-75 mg/kg was consid-
ered for the present study. The pregnant mice were 
then assigned to four groups; group 1 (control one; 
32 offspring obtained) received no treatment, group 
2 (control two; 31 offspring obtained) was intraperi-
toneally administered with 1 ml ethanol three times 
a day (every 8 hours) from the gestational day 9, 
and groups 3 (treatment one; 36 offspring obtained) 
and 4 (treatment two; 18 offspring obtained) were 
intraperitoneally administered with LTG at 25 and 
75 mg/kg doses, respectively.
On gestational day 18, all the mice were anes-
thetized and killed through cervical dislocation. 
Then, the embryos were taken out of the fallopian 
tube by opening an anterior abdominal wall and 
separately examined for superficial morphology, 
as well as vertebral, limb, and cranial anomalies 
upon the removal of fetal membranes. Three types 
of anomalies consisting of vertebral (scoliosis and 
kyphosis), limb (amelia and micromelia), and cranial 
(exencephaly and anencephaly) were evaluated and 
the incidence rates of resulting complications for the 
four studied groups were compared. The weight of 
fetuses was then measured using a digital weight 
(Sartorius) to the nearest 0.01 g and their height 
(crown-rump length) was measured using a caliper 
to the nearest 0.1 mm. The obtained data were 
analyzed by Kruskal-Wallis H test and Chi-square 
test using SPSS Statistics (Version 22) and levels 
of significance were considered by <0.05.
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RESULTS
The findings of the study are summarized in Table 
1. Figs 1 and 2 also illustrate some emerged 
anomalies in the formation of fetal extremities. 
Based on the findings, ethanol caused a decrease 
in weight and height. Once LTG was introduced, 
a significant descending trend in weight and height 
was also observed, that was further increased by 
adding the dose (p<0.001). The incidence rates of 
anomalies among the four groups were also com-
pared in Table 1. In groups 3 and 4, the incidence 
rates of anomalies increased as the dose of LTG 
was administered. Table 2 shows the number and 
percentage of observed skeletal anomalies in mouse 
fetuses in the four study groups. Anomalies were 
observed in the sham group (receiving only the 
solvent) and treatment groups but the difference 
between the sham group and treatment groups was 
reported to be significant (p< 0.05). Notably, 5 min 
after administration of LTG at 75 mg/kg, myoclonic 
contractions were initiated and continued for 2 to 
3 minutes. During pregnancy, following the admin-
istration of lamotrigine, 1 and 3 deaths in the 25 
and 75 mg/kg groups were observed, respectively.
DISCUSSION
Treatment of epilepsy in pregnant women can be 
consistently associated with many complications, so 
fetuses exposed to AEDs are more predisposed to 
various problems.15,23 Lamotrigine, one of the novel 
anti-epileptic medications, is widely used either 
alone or in combination with other medications for 
treating epileptic seizures in adults and children. 
There is also enough evidence showing that LTG 
passes through the placenta easily and is secreted 
in the breasts.24 Moreover, LTG is classified as a 
group C drug and its use is limited to the treatment 
of various types of epilepsy according to Food and 
Drug Administration.24 However, since this medica-
tion can contribute to the treatment of other chronic 
neurological diseases including bipolar disorder and 
migraine with aura, trigeminal syndrome is increas-
ing.11,25,26 Given that the available data regarding 
teratogenic effects of LTG are scarce, previous studies 
have mostly considered oral intake of this drug.3,27 
Furthermore, it is increasingly being taken for the 
treatment of many neurological diseases. Thus, the 
purpose of this study was to investigate the in vivo 
teratogenic effects of LTG on mice fetuses.
The study of superficial characteristics and 
anomalies in the fetuses of the mice administered 
with LTG have indicated some variations in the 
course of growth and development as well as mor-
phogenesis of these fetuses (Table 1). As shown in 
Table 1. Comparison of height, weight, and anomalies in mice fetuses among different groups. p-values indicate 
comparison between treatment groups (receiving 25 and 75 mg/kg lamotrigine) and control 2 (sham) group








Median weight (g) 1.38 0.99 0.865 <0.001 0.84 <0.001
Median height (mm) 2.615 2.04 2 <0.05 1.795 <0.001
Rate of anomalies (%) 0.0% 16.1% 50% <0.001 52.8% <0.001
Table 2. Frequency and percentage of observed skeletal anomalies in mice fetuses of four study groups








Scoliosis 0 2 (6.5 %) 13(36.1%) <0.001 7(38.9%) < 0.001
Costal fusion 0 5 (16.1 %) 11(30.6%) <0.05 6(33.3%) <0.05
Bifurcation 0 4 (12.9%) 11(30.6%) <0.05 6(33.3%) <0.05
*Mice in the control group did not receive anything.
#Mice in the sham group received only the solvent.
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Table 1, there was a significant difference in terms 
of height and weight among the four study groups. 
In group 2, a decrease in weight and height after 
administrating ethanol as a LTG solvent was seen 
compared to group 1.
Consistent with previous investigations,7,15,28 
the findings of the present study indicated that the 
height and the weight of the fetuses had significantly 
decreased once LTG had been administrated in a 
dose-dependent manner (Table 1).
Decreased height and weight could be due to 
a variety of reasons, but researchers generally ar-
gued that the use of AEDs during pregnancy could 
cause decreases in total protein content within the 
fetuses and consequently a decline in height and 
weight.27 Obviously, LTG during pregnancy could 
be considered as a risk factor for fetal growth and 
development whilst potentially causing reductions in 
the weight and height of the fetuses. The obvious 
anomalies in the present study included scoliosis 
and kyphosis (in vertebrae), amelia and micromelia 
(in limbs), as well as unencephaly and exencephaly 
(in cranium). Based on the findings of this investi-
gation, various anomalies increased in group 2 in 
comparison with group 1, but the incidence rate of 
anomalies significantly increased with the addition 
of LTG in a dose-dependent manner in groups 3 
and 4. There are also several discrepancies among 
previous reports in terms of determining whether 
LTG has teratogenic effects in human fetuses of not.
The results of previous studies have indicated 
that oral intake of LTG in mice and rats at doses 
1.2 times higher than the one used by humans 
(500 mg/kg) can be associated with no anomalies 
but could lead to preterm birth and decreased fetal 
weight.14,27 However, Bastaki et al. and Padmanab-
han et al. found that intraperitoneal administration 
of LTG, at doses above 75 mg/kg, could result in 
craniofacial anomalies such as cleft palate, exen-
cephaly, and caudal.15,29
LTG can easily pass through the placenta and 
therefore affect fetal development and lead to anoma-
lies.30 The mechanism through which LTG causes 
anomalies remains to be adequately explained. It is 
believed that this drug decreases fetal folate levels 
that would be a main factor contributing to the 
development of congenital anomalies in humans.29,31 
Essentially, because of these reasons, daily intake 
of 5 mg folic acid alongside AEDs, including LTG, 
in the first trimester helps to considerably decrease 
teratogenic effects.32 Other evidence has indicated 
that the inclusion of serum levels methionine and 
free radicals produced by AEDs may be involved 
in the emergence of congenital anomalies in the 
fetus of pregnant women with epilepsy being treated 
with this drug.6,7,15
CONCLUSIONS
In conclusion, the use of LTG during pregnancy 
throughout organogenesis could have potential 
teratogenic effects and disturb fetal growth and 
development. In this study, ethanol as a substance 
with well-known teratogenic action was used for 
dissolving lamotrigine. Since the final concentration 
of injected ethanol for each mouse was less than 
2%, less adverse effects of emerging anomalies 
Figure 1. Anomalies in the formation of fetal extremi-
ties in the embryo administered with lamotrigine at 
25 mg/kg.
Figure 2. Kyphosis and aplasia of the right upper 
limb in the embryo administered with lamotrigine 
at 75 mg/kg.
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were experienced; so the obtained results should 
be interpreted with caution. According to these 
results, lamotrigine could be considered as a risk 
factor for the development of anomalies. The po-
tentially decreased serum concentrations of folate 
and methionine could contribute to induce these 
anomalies. Therefore, more studies are needed to 
further investigate the effects of this medication and 
explain the relevant mechanisms.
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Введение: Приём антиэпилептических препаратов во время беременности 
может быть связан с повышенным риском тератогенности, а также врож-
дённых аномалий. Тем не менее, существует много противоречивых мнений 
о том, может ли ламотриджин, как противоэпилептическое лекарственное 
средство, в значительной степени индуцировать пороки развития у новоро-
жденных или нет. Таким образом, целью исследования является установле-
ние тератогенного воздействия ламотриджина на эмбрион мыши.
Материалы и методы: В настоящем исследовании 21 беременная мышь 
были распределены в 4 группы. Группы 1 и 2 (контрольные) были подвергну-
ты фиктивной обработке и 20% этанолу соответственно. Группы 3 и 4 (прохо-
дившие лечение) получали 25 и 75 мг / кг в течение 3 дней. Протокол лечения 
был выполнен в рамках 9-18 гестационного дня для всех групп. На 18-й день 
беременности 117 эмбрионов были удалены из маточных труб исследован-
ных мышей и затем исследованы на наличие аномалий (позвоночника, конеч-
ностей и черепной коробки) с последующим измерением их роста и веса.
Результаты: Результаты показали, что в обработанных группах вес и рост 
были значительно снижены (р <0,01) и установлено наличие различных ано-
малий. Кроме того, с увеличением дозы ламотриджина нарастали снижение 
веса, роста и тенденция к росту количества аномалий.
Заключение: Согласно полученным данным, ламотриджин можно рассма-
тривать как фактор риска развития исследованных  аномалий.
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